Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Immunotherapies have revolutionized intervention strategies for many primary cancers, but
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Tumours with an immunosuppressive microenvironment respond poorly to therapy.
Activation of the stimulator of interferon genes (STING) pathway can enhance intratumoural …

Postsurgical treatment of glioblastoma multiforme (GBM) by systemic chemotherapy and
radiotherapy is often inefficient. Tumor cells infiltrating deeply into the brain parenchyma are …